12 results about "Acute leukemia" patented technology

This invention relates to the application of PGG in the preparation of drugs for treating acute leukemia, belonging to the field of biomedical technology. To address the problems of narrow application range and easy development of drug resistance in existing acute leukemia treatments, this invention provides the application of PGG in the preparation of drugs for treating acute leukemia. Experiments have shown that PGG can inhibit the viability, proliferation, and colony formation of human acute myeloid leukemia cells (MOLM-13) and human acute lymphoblastic leukemia cells (Jurkat), and induce their apoptosis. In animal models, intraperitoneal injection of PGG can prolong the survival days of mice with acute leukemia and reduce the infiltration of leukemia cells in the liver, spleen, and bone marrow tissues. In this invention, PGG directly inhibits the viability of acute leukemia cells and can simultaneously inhibit AML and ALL, without relying on specific gene mutations, resulting in a lower risk of drug resistance, more flexible clinical use, and broader patient coverage, showing promising clinical application prospects.

The application discloses a kind of pyrimidopyrazole derivatives and its medical purposes.The pyrimidopyrazole derivatives are the compounds shown in general formula I, its pharmaceutically acceptable salt or solvate, the compound of the application can be used as ALKBH5 protein small molecule inhibitor, inhibits RNA demethylase at the level of protease, and can be used for treating acute leukemia, lung cancer, breast cancer, colon cancer, prostate cancer, pancreatic cancer, gastric cancer, liver cancer, ovarian cancer, kidney cancer, neuroglioma, melanoma, myeloma, lymphoma, bladder cancer or cervical cancer.

The present application relates to a kind of acute leukemia (ALL) high flux flow detection kit, belong to leukemia detection field, the present application is based on the original 8 color flow to increase 16 kinds of ALL cell antigen, can realize the simultaneous detection of 24 kinds of antigens in the same cell, not only greatly improve the detection precision of micro residual lesion (MRD), and by being divided into 12 development stages to ALL cell, can more accurately identify immunotyping when first diagnosis, and immunophenotypic aberration after bone marrow transplantation and after CAR-T cell therapy, this has very important guiding significance to the evaluation of patient treatment effect and the adjustment of treatment scheme.

The application of DNTTIP1 gene in preparing acute leukemia treatment drugs belongs to the technical field of biological medicine, and provides a new solution to the preparation of acute leukemia treatment drugs. The present application uses DNTTIP1 gene as a biomarker drug target, and combines the inhibitor MS-275 of the interaction protein HDAC1 of DNTTIP1 and the downstream target gene BMF analog ABT199 to prepare acute leukemia treatment drugs. The deletion of deoxynucleotide transferase terminal interaction protein 1 gene DNTTIP1 will damage the recruitment of histone deacetylase 1 HDAC1 to chromatin, cause high acetylation of histone H3 lysine 27 on B-cell lymphoma 2 modifier factor BMF promoter, and re-activate BMF. The re-activated BMF competitively destroys the BCL2-mediated survival pathway, triggers coordinated autophagy and apoptosis.

The present application relates to the technical field of risk prediction based on medical record data, and particularly relates to an acute leukemia relapse risk stratification early warning method. Based on the similar situation of relapse influencing factor values between historical medical record samples and the similar situation of first relapse intervals, the similarity of relapse influencing factor values of the historical medical record samples and the current medical record sample is adjusted to screen similar samples and preliminarily quantify the relapse risk value of the current medical record sample. Further, the relapse risk change curve is fitted by combining the first relapse interval difference, the relapse influencing factor difference and the adverse habit characteristic value difference between the historical medical record samples, and the influence law of the dynamic change of the adverse habit on the relapse risk is quantified. Finally, the adverse habit characteristic value difference of the current medical record sample from discharge to the current time is mapped to the curve to obtain the relapse risk change amount, and the relapse risk value is fused to form a dynamically adjusted risk assessment index, thereby improving the accuracy of the relapse risk early warning of the current medical record sample.

The invention provides triterpenes in a Yunnan subfoliate plant, a pharmaceutical composition of the triterpenes and application of the triterpenes, provides four new pomurine type triterpenes 1-4 with the English name of phyllanfranchins A-D as shown in a structural formula (I), a pharmaceutical composition of the four new pomurine type triterpenes and application of the four new pomurine type triterpenes, and belongs to the technical field of medicines. The compounds 1-4 provided by the invention have remarkable cytotoxic activity on human acute leukemia cells HL-60 and K562, lung cancer cells A-549, liver cancer cells HepG2, breast cancer cells MDA-MB-231 and colon cancer cells SW-480, have small toxicity on normal human pulmonary epithelium BEAS-2B, and can form a pharmaceutical composition with a pharmaceutically acceptable carrier to be used for preparing related anti-cancer drugs.

The present application relates to the biomedical technology field, and more particularly to a diagnostic kit based on acute leukemia prognosis and drug sensitivity prediction, comprising prediction module I and prediction module II.Prediction module I is used for predicting the clinical survival rate of patients, and one or more of 32 molecules such as CCND3, FERMT3 and PLD4 is used as a prognostic marker; prediction module II is used for predicting the sensitivity of the body to drugs, and one or more molecules of BMP8B, IGF1R, OTULINL, SLC22A15, CERS1 and PDE4A are used as drug sensitivity markers.The present application breaks through the limitations of single biomarker prediction efficiency by constructing a double prediction model, realizes the functional coupling of survival prognosis and multiple drug sensitivity prediction, and provides an integrated tool for clinical transformation for AML precise treatment.

Methods for classifying cancers to aid in diagnosis and treatment of the cancer, in particular acute leukemia and solid tumors such as pediatric sarcomas, in a rapid manner (less than 24 hours). Methods comprising the use of long-read whole genome sequencing of libraries comprising high molecular weight DNA to identify copy number variations and / or presence or absence of a mutation such as a karyotype abnormality or translocation / gene fusion in a panel of targets and treatment of patients based upon cancer classification.

The invention relates to the technical field of risk prediction based on medical record data, in particular to an acute leukemia recurrence risk layered early warning method. Based on the similar situation of the recurrence influence factor values among the historical medical record samples and the similar situation of the first recurrence interval, adjusting similar characteristics of the recurrence influence factor values of the historical medical record samples and the current medical record sample to screen similar samples and preliminarily quantify the recurrence risk value of the current medical record sample; furthermore, a recurrence risk change curve is fitted by combining first recurrence interval difference, recurrence influence factor difference and bad habit characteristic value difference among historical medical record samples, and an influence rule of bad habit dynamic change on the recurrence risk is quantified. And finally, the bad habit characteristic value difference of the current medical record sample from discharge to the current moment is mapped to a curve, a recurrence risk variable quantity is obtained and fused with a recurrence risk value, a dynamically adjusted risk assessment index is formed, and the accuracy of recurrence risk early warning of the current medical record sample is improved.

Compounds and pharmaceutical compositions comprising compounds that inhibit ENL / AF9 YEATS and FLT3 are disclosed herein. Methods for suppressing oncogene expression in a cell, or for treating acute leukemias, using the compounds and pharmaceutical compositions comprising the compounds are also disclosed. The compounds, pharmaceutical compositions and methods can be used to inhibit key drivers of cancer and cancer stem cell survival.

The present application relates to a kind of recombinant complement protein and the application in the preparation of anti-leukemia drugs, belong to biological medicine technical field;The present application discloses that single drug treatment, i.e. injection recombinant C1QBP protein has significant effect in the treatment of acute leukemia, can significantly inhibit the proliferation of leukemia cells in hematopoietic system bone marrow, spleen, peripheral blood, while inhibiting the infiltration of leukemia cells in extramedullary organs (skin, etc.), thereby reducing the whole body tumor load, significantly prolonging the survival period of leukemia mouse.Recombinant C1QBP protein is combined with clinical first-line chemotherapy regimen, has synergistic effect, compared with single use chemotherapy drug has stronger effect of inhibiting the proliferation of leukemia cells, can significantly prolong the survival period of leukemia mouse, has played the effect of attenuated and synergistic effect.The present application first proves that complement C1Q binding protein has the effect of treating leukemia, and provides preparation method and combined drug regimen, has higher clinical conversion prospect and application value.

Provided herein are methods of treating acute leukemia, such as acute myeloid leukemia (AML), in an individual, comprising administering to the individual a menin inhibitor and a standard-of-care therapy.